Advertisement

Cyclovirobuxine

  • Xiao-Li He
  • Shou-Bao Wang
  • Guan-Hua DuEmail author
Chapter

Abstract

Cyclovirobuxine is an alkaloid extracted from common boxwood (Buxus microphylla Sieb. et Zucc. var. sinica Rehd. et Wils) and its genus. Its chemical structure is a derivative of pregnane. Cyclovirobuxine is a new Chinese medicine that is successfully developed for the treatment of cardiovascular diseases in recent years. After decades of clinical observation, cyclovirobuxine has the therapeutic role of anti-myocardial ischemia and antiarrhythmia and protects against acute cerebral ischemia. In addition, cyclovirobuxine can cross the blood-brain barrier and improve brain microcirculation and oxygen supply to treat cerebral arteriosclerosis insufficiency. In all, it has potent curative effects and low risk of side effects. The safety of oral administration of cyclovirobuxine is excellent, while the risk of side effects in long-term use is low, which indicates that this drug has a good application prospect.

Keywords

Cyclovirobuxine Alkaloid Anticardiovascular Anticerebrovascular 

References

  1. 1.
    Brown KS Jr, Morris Kupchan S. Buxus alkaloids. VI. The constitution of Cyclovirobuxine-D. Tetrahedron Lett. 1964;5(39):2895–900.CrossRefGoogle Scholar
  2. 2.
    Fang TH, Wu BY, Yao MH, et al. The experimental research of Buxine no.1 on acute myocardial ischemia. Acta Acad Med Wannan. 1979;10:18–34.Google Scholar
  3. 3.
    Wang LZ, Shan WD. The isolation and identification of Cyclovirobuxine D from Buxus microphylla Sieb. Zucc. var. sinica Rehd. et Wils (Xiaoyehuangyang). Study Chin Tradit Pat Med. 1979;4:24–6.Google Scholar
  4. 4.
    Wang LZ, Shan WD. The isolation and identification of Cyclovirobuxine D from Buxus microphylla Sieb. Zucc. var. sinica Rehd. et Wils (Xiaoyehuangyang). Jiangsu Med J. 1979;10:14–6.Google Scholar
  5. 5.
    The Anhui Huangyang Research Cooperation Group. The experimental research of Buxine no. 1 on coronary heart disease. Acta Acad Med Wannan. 1984;3:50–3.Google Scholar
  6. 6.
    Liang T, Fang TH, Yao XJ, et al. The pharmacological research progress of Cyclovirobuxine D. Pharm J Chin People's Liberation Army. 2001;17(1):35–8.Google Scholar
  7. 7.
    Yu MQ, Xu L, Fang TH, et al. Pharmacology and toxicology overview of Cyclovirobuxine D. Anhui Med Pharm J. 2008;12(10):885–7.Google Scholar
  8. 8.
    Fang TH, Xu HQ. Protective action of Huangyangning against acute experimental cerebral ischemia in mice. Chin Tradit Herb Drug. 1997;7:413–4.Google Scholar
  9. 9.
    Yuan DP, Long J, Fang TH. Protective effect of CBV-D on Glu-induced injury in cultured PC12 cells. Chin J Integr Med Cardiol-/Cerebrovas Dis. 2004;2(1):37–8.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. and People's Medical Publishing House, PR of China 2018

Authors and Affiliations

  1. 1.Institute of Medicinal Plant DevelopmentChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
  2. 2.Beijing Key Laboratory of Drug Targets Identification and Drug Screening, Centre for Pharmaceutical Screening, Institute of Materia MedicaChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Personalised recommendations